Skip to main content
. 2023 Oct 31;16:171–183. doi: 10.1016/j.sopen.2023.10.008

Table 3.

The efficacy of different treatment groups between CR/PR and SD/PD.

Group 1
Group 2
UX first-line therapy (n = 9) UX second-line or above therapy (n = 31) P-value UX first-line therapy (n = 9) NP first-line therapy n = 60 P-value
CR/PR 3 5 0.348 3 11 0.373
SD/PD 6 26 6 49

CR complete response, PR partial response, SD stable disease, PD progressive disease, UX (Utidelone plus Capecitabine); NP (Vinorelbine plus Cisplatin).